No connection

Search Results

AGIO vs IMCR

AGIO
Agios Pharmaceuticals, Inc.
BEARISH
Price
$27.85
Market Cap
$1.63B
Sector
Healthcare
AI Confidence
85%
IMCR
Immunocore Holdings plc
BEARISH
Price
$31.05
Market Cap
$1.57B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
AGIO
--
IMCR
--
Forward P/E
AGIO
-5.74
IMCR
-22.02
P/B Ratio
AGIO
1.36
IMCR
4.13
P/S Ratio
AGIO
30.2
IMCR
3.94
EV/EBITDA
AGIO
-1.75
IMCR
-51.28

Profitability

Gross Margin
AGIO
0.0%
IMCR
96.53%
Operating Margin
AGIO
-608.89%
IMCR
0.03%
Profit Margin
AGIO
0.0%
IMCR
-8.88%
ROE
AGIO
-30.2%
IMCR
-9.58%
ROA
AGIO
-19.93%
IMCR
-1.54%

Growth

Revenue Growth
AGIO
86.1%
IMCR
24.3%
Earnings Growth
AGIO
--
IMCR
--

Financial Health

Debt/Equity
AGIO
0.03
IMCR
1.15
Current Ratio
AGIO
11.46
IMCR
4.04
Quick Ratio
AGIO
10.53
IMCR
3.91

Dividends

Dividend Yield
AGIO
--
IMCR
--
Payout Ratio
AGIO
0.0%
IMCR
0.0%

AI Verdict

AGIO BEARISH

AGIO's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates poor operational and financial health, while the absence of an Altman Z-Score raises red flags for potential bankruptcy risk. Despite strong revenue growth of 86.1% YoY, the company reports a 0.00% profit margin, negative operating margin of -608.89%, and negative ROE of -30.20%, signaling deep operational inefficiencies. Insider selling activity totaling $2.06M over six months, with multiple officer sales, underscores lack of confidence from within the organization. The stock trades at a premium valuation (Price/Sales of 30.20) with no earnings or cash flow support, and its 52-week high is 65% above current levels, indicating overvaluation relative to fundamentals.

Strengths
Strong revenue growth of 86.1% YoY, indicating market traction and product demand
High analyst consensus with a 'buy' recommendation from 8 analysts
Extremely low debt/equity ratio of 0.03, suggesting minimal leverage risk
Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and weak operational performance
Negative operating margin (-608.89%) and zero profit margin reflect unsustainable business model
Insider selling of 35,569 shares ($2.06M value) signals internal skepticism
IMCR BEARISH

IMCR exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. While the company maintains an impressive gross margin of 96.53% and positive revenue growth of 24.3%, these are offset by a catastrophic year-over-year EPS decline of 452.9% and a bearish insider sentiment. There is a stark disconnect between the aggressive analyst target price of $63.86 and the actual deterministic data, which suggests a high-risk profile characterized by consistent earnings misses and insider liquidation.

Strengths
Exceptional gross margins (96.53%) typical of high-value biotech products
Strong short-term liquidity with a current ratio of 4.04
Consistent positive revenue growth (24.3% YoY)
Risks
Critical financial health failure (Piotroski F-Score 1/9)
Severe earnings collapse with YoY EPS growth of -452.9%
Bearish insider activity with $4.35M in sales and zero buys

Compare Another Pair

AGIO vs IMCR: Head-to-Head Comparison

This page compares Agios Pharmaceuticals, Inc. (AGIO) and Immunocore Holdings plc (IMCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile